Marzban Abbas Abadi Mobin, Emadian Seyedeh Tahereh, Zamani Mohammad, Khalilizad Majid
Departments of Orthopedic and Trauma Surgery, Babol University of Medical Sciences, Babol, Iran.
Non-communicable Pediatric Research Center, Health Research Institute, Babol University of Medical Sciences, Babol, Iran.
J Health Popul Nutr. 2025 May 29;44(1):178. doi: 10.1186/s41043-025-00946-8.
Although prior studies alluded to the association between inflammatory bowel disease (IBD) and osteoporosis, the exact prevalence of osteoporosis in this patient population remains variably reported. Therefore, we aimed to systematically explore the overall prevalence of osteoporosis in patients with IBD.
We searched in Embase, PubMed, and Scopus, from the inception until 31 May 2024. We included studies that reported cross-sectional data on the prevalence of osteoporosis in at least 100 adult (≥ 18 years) patients with IBD. We combined the data extracted from the eligible studies to obtain pooled estimates using a random-effects model.
A total of 24 articles were included, comprising 417,298 patients with IBD. Our analysis showed that the overall pooled prevalence of osteoporosis in IBD patients was 12.2% (95% confidence interval [CI]: 9.1-15.3; I = 99.7%), with varying rates by country. We also found that the osteoporosis risk in patients with IBD increased versus controls (pooled odds ratio = 1.64, 95% CI: 1.24-2.16). There were no significant differences in the prevalence of osteoporosis by disease type (Crohn's disease, 14.9% [95% CI: 8.8-20.9]; ulcerative colitis, 11.4% [95% CI: 5.8-17.0]; p for interaction = 0.408) and sex (men, 9.6% [95% CI: 3.0-16.3]; women, 10.5% [95% CI: 6.8-14.1]; p for interaction = 0.832).
There is a significant prevalence of osteoporosis in patients with IBD, though variations by disease type and sex are not probably observed. We witnessed high heterogeneity among the studies. Tailored approaches are warranted for osteoporosis screening and management in this patient population.
尽管先前的研究提及炎症性肠病(IBD)与骨质疏松症之间的关联,但该患者群体中骨质疏松症的确切患病率报道不一。因此,我们旨在系统地探究IBD患者中骨质疏松症的总体患病率。
我们在Embase、PubMed和Scopus数据库中进行检索,检索时间从建库至2024年5月31日。我们纳入了报告至少100名成年(≥18岁)IBD患者骨质疏松症患病率横断面数据的研究。我们使用随机效应模型合并从符合条件的研究中提取的数据,以获得汇总估计值。
共纳入24篇文章,包含417,298例IBD患者。我们的分析表明,IBD患者中骨质疏松症的总体汇总患病率为12.2%(95%置信区间[CI]:9.1 - 15.3;I² = 99.7%),不同国家的患病率有所不同。我们还发现,与对照组相比,IBD患者的骨质疏松症风险增加(汇总比值比 = 1.64,95% CI:1.24 - 2.16)。按疾病类型(克罗恩病,14.9% [95% CI:8.8 - 20.9];溃疡性结肠炎,11.4% [95% CI:5.8 - 17.0];交互作用p值 = 0.408)和性别(男性,9.6% [95% CI:3.0 - 16.3];女性,10.5% [95% CI:6.8 - 14.1];交互作用p值 = 0.832)划分,骨质疏松症的患病率无显著差异。
IBD患者中骨质疏松症的患病率较高,尽管未观察到疾病类型和性别方面的差异。我们发现研究之间存在高度异质性。针对该患者群体的骨质疏松症筛查和管理,需要采取针对性的方法。